Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,863 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 319 · Balance 87,863 F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2019 Filed Jun 10, 2019 20:10 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001534424-19-000176 · ownership.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:06 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 953 | $3.15 | $3,001.95 |
DisclosureSEC source: 0001534424-19-000099 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,664 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:10 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,040 | $1.47 | $2,998.80 |
DisclosureSEC source: 0001534424-19-000011 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,711 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:44 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,707 | $1.76 | $3,004.32 |
DisclosureSEC source: 0001534424-18-000338 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,671 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:09 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,377 | $2.18 | $3,001.86 |
DisclosureSEC source: 0001534424-18-000241 · richards.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,964 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 12:53 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001534424-18-000209 · richards.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 20:57 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 958 | $3.13 | $2,998.54 |
DisclosureSEC source: 0001534424-18-000113 · richards.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,587 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:23 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000501 · richards.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.